Fri. Nov 27th, 2020

Moderna’s coronavirus vaccine shows promise in early results

The biotech company Moderna announced Monday (May 18) that their experimental coronavirus vaccine showed promising results in an early trial, known as a phase I study.

After receiving a single dose of the vaccine, called mRNA-1273, all 45 of the participants in the trial developed detectable levels of antibodies within 15 days, according to a statement from Moderna, which is based in Cambridge, Massachusetts.